Clinical Trials for Inflammatory Bowel Disease

190 inflammatory bowel disease trials indexed, 96 currently recruiting. Updated daily from ClinicalTrials.gov.

Understanding Inflammatory Bowel Disease

Inflammatory Bowel Disease (IBD) refers to a group of chronic disorders that cause inflammation in the digestive tract. The two main types of IBD are Crohn’s disease and ulcerative colitis. These conditions involve an abnormal immune response where the body’s immune system mistakenly attacks the gastrointestinal tract, leading to ongoing inflammation. Diagnosis typically involves a combination of medical history, physical exams, laboratory tests, endoscopy, and imaging studies. Biopsies taken during endoscopy help confirm the presence of inflammation and rule out infections or other causes.

Common symptoms of IBD include persistent diarrhea, abdominal pain, rectal bleeding, weight loss, and fatigue. The disease often starts in adolescence or early adulthood, with many cases diagnosed between ages 15 and 35. Both men and women are affected, but certain risk factors increase the likelihood of developing IBD. These include a family history of the disease, smoking (especially for Crohn’s disease), and living in urban or industrialized regions. Environmental factors, such as diet and exposure to certain infections, may also play a role in triggering the disease.

IBD is a significant medical and social concern due to its chronic nature and impact on quality of life. It is estimated that about 3 million adults in the United States have some form of IBD. Beyond symptoms, the disease can lead to complications like strictures, fistulas, and increased risk of colorectal cancer. Economically, IBD imposes a substantial burden, with annual healthcare costs in the U.S. exceeding $30 billion. This includes hospitalizations, surgeries, medications, and lost productivity. Understanding IBD helps highlight the importance of ongoing research and improved treatment options.

The Inflammatory Bowel Disease Treatment Landscape

The first-line treatment for IBD usually involves anti-inflammatory medications to reduce gut inflammation and control symptoms. Aminosalicylates (5-ASAs) such as mesalamine are often prescribed for mild to moderate ulcerative colitis. Corticosteroids may be used for short-term flare control but are not recommended for long-term use due to side effects. Treatment is typically adjusted based on disease severity, location, and patient response. In many cases, doctors follow a step-up approach, starting with less aggressive drugs and moving to stronger therapies if needed.

When first-line treatments are not effective or suitable, second- and third-line options come into play. Immunomodulators like azathioprine and methotrexate help suppress the immune system to maintain remission. Biologic therapies, including anti-TNF agents such as infliximab and adalimumab, target specific molecules involved in inflammation. Newer biologics and small molecules, like integrin receptor antagonists and Janus kinase inhibitors, offer additional options for patients who do not respond to traditional drugs. Surgery may be considered when medications fail to control symptoms or complications arise.

Despite advances in treatment, many patients still face challenges. Some subgroups respond poorly or develop resistance to current therapies. Side effects such as infections, liver toxicity, and increased cancer risk limit long-term use for certain drugs. There is also a need for treatments that provide sustained remission without immunosuppression. Research efforts focus on identifying new drug targets, improving personalized medicine approaches, and developing therapies with better safety profiles. Clinical trials continue to explore these gaps in care to improve outcomes for people living with IBD.

Why Clinical Trials Matter for Inflammatory Bowel Disease

Clinical trials offer important opportunities for patients with IBD to access new treatments that are not yet widely available. These studies provide closer medical monitoring and contribute valuable data to improve understanding of the disease. According to ClinicalTrials.gov, there are currently 190 inflammatory bowel disease clinical trials indexed, with 96 actively recruiting participants. This wide range of trials covers various treatment approaches, including new drugs, dietary interventions, and surgical techniques. Participation in a trial can help advance care for future patients.

It is important to consider the risks involved with clinical trial participation. Some treatments may not prove effective or could cause unexpected side effects. Many trials include placebo-controlled groups, meaning some participants receive an inactive treatment to compare results. Additional clinic visits, tests, and procedures may be required, which can take extra time and effort. Patients should discuss these factors with their healthcare team to make informed decisions about joining a trial.

The landscape of IBD clinical trials includes sponsors from academic institutions, pharmaceutical companies, and cooperative research groups. Each plays a role in developing and testing new therapies. ClinicalTrials.gov serves as a central registry where patients and providers can find detailed information about ongoing studies. This transparency helps match interested individuals with appropriate trials and supports collaboration across the research community. Overall, clinical trials remain a key part of efforts to improve treatment options for inflammatory bowel disease.

What to Look for in a Inflammatory Bowel Disease Clinical Trial

Clinical trials are divided into four main phases. Phase 1 trials focus on safety and dosage, usually involving a small number of healthy volunteers or patients. Phase 2 trials test the effectiveness of the treatment and further evaluate safety. Phase 3 trials involve larger groups to confirm effectiveness, monitor side effects, and compare with standard treatments. Phase 4 trials happen after approval to gather more information on long-term effects. For inflammatory bowel disease, the distribution of trials shows the most activity in Phase 2 with 43 studies, followed by 38 studies where the phase is not specified. Phase 3 includes 29 trials, and Phase 1 has 18 trials. This means many studies are still assessing treatment effectiveness and safety before moving to larger populations.

Inclusion criteria determine who can join a clinical trial. For inflammatory bowel disease, these often include age limits, typically adults between 18 and 65 years old, though some trials accept younger or older participants. Prior treatments may be considered, such as requiring patients to have tried certain medications without success. Biomarkers or specific disease characteristics may also be required, like inflammation levels or disease subtype (Crohn’s disease or ulcerative colitis). The stage or severity of the disease and how long the patient has had the condition often matter too. These criteria help ensure that the trial results apply to a specific group of patients.

Exclusion criteria are just as important because they protect patients and the quality of the study. Common reasons for exclusion include having other health conditions that might interfere with the treatment or increase risk, such as heart disease or infections. Some drugs can interact badly with trial medications, so patients taking certain medicines might not be allowed. Safety thresholds like abnormal liver or kidney function tests can also exclude patients. These rules help keep participants safe and ensure that the trial results are clear and reliable.

From a patient’s perspective, practical details matter a lot. Trials can last weeks to months or longer, requiring regular visits to the study site. Travel distance and frequency of visits can affect participation. Patients should ask the research team key questions: How long will the trial last? What types of tests and procedures are involved? What are the possible side effects? Will the trial cover travel or other costs? Understanding these factors helps patients decide if a trial fits their needs and lifestyle.

Primary Sources and Further Reading

For those interested in learning more about inflammatory bowel disease and clinical trials, reliable sources provide detailed and up-to-date information. These resources offer guidance on symptoms, treatment options, and how to participate in research studies. Exploring these sites can help patients and caregivers make informed decisions about their health and clinical trial participation.

Latest Research and Emerging Treatments for Inflammatory Bowel Disease (2026)

Recent inflammatory bowel disease research includes several Phase 3 trials testing new drugs that may improve treatment options. Duvakitug, studied in adults with moderately to severely active Crohn's disease (NCT07184931, NCT07184944), is one such drug. It is designed to reduce inflammation by targeting specific immune pathways involved in the disease. These trials assess both the initial effectiveness and the long-term safety of duvakitug, with participants monitored for up to 286 weeks. If successful, this treatment could help reduce symptoms and improve quality of life for patients who struggle with current therapies.

For children with inflammatory bowel disease, new research is exploring biologic treatments like vedolizumab and guselkumab. Vedolizumab (NCT05442567) works by blocking certain immune cells from reaching the intestines, which may reduce inflammation and prevent damage. This study focuses on the safety of vedolizumab in children with ulcerative colitis or Crohn's disease over a long period. Another biologic, guselkumab (NCT05923073), targets a protein involved in the immune response, potentially helping children with moderate to severe Crohn's disease. These new drugs for inflammatory bowel disease could offer additional options for pediatric patients who need alternatives to existing treatments.

Afimkibart (NCT07158242) is also being tested in children with moderately to severely active ulcerative colitis. This drug belongs to a class that may block inflammatory signals in the gut, helping to control symptoms over time. Trials like these reflect ongoing efforts to find inflammatory bowel disease new treatment 2026 options that are both effective and safe for different age groups. For patients and caregivers, these studies represent hope for more personalized and manageable treatment plans in the future.

Frequently asked questions about Inflammatory Bowel Disease trials

How do I find Inflammatory Bowel Disease clinical trials?

The authoritative source for Inflammatory Bowel Disease clinical trials is ClinicalTrials.gov, maintained by the U.S. National Library of Medicine. 190 inflammatory bowel disease studies are currently indexed. You can search by entering "inflammatory bowel disease" as the condition, then filter by recruiting status, phase, and location. TrialsAlert scans ClinicalTrials.gov daily for new inflammatory bowel disease trials and delivers a plain-language briefing every Friday explaining what changed.

What phase are most Inflammatory Bowel Disease trials in?

Across the 190 inflammatory bowel disease trials TrialsAlert indexes, the most common phase is Phase 2. Early-phase studies (Phase 1 and Phase 2) test safety and initial efficacy. Phase 3 trials compare a candidate treatment against the current standard of care in larger populations and generate the evidence regulators use to approve new therapies.

How many Inflammatory Bowel Disease clinical trials are currently recruiting?

As of the latest scan, 96 inflammatory bowel disease trials have a "Recruiting" status on ClinicalTrials.gov, out of 190 total indexed. The recruiting figure changes daily as studies open, fill enrollment, and close. TrialsAlert subscribers are notified when a new recruiting inflammatory bowel disease trial matches their tracked condition.

Stay informed about inflammatory bowel disease research

Get a weekly briefing with the trials that matter most.

Start monitoring inflammatory bowel disease trials